Soleno Therapeutics (SLNO) investor relations material

Commercial performance and launch trajectory

• Achieved 10% of total addressable market (TAM), about 1,000 patients, in first six months, aiming to repeat this cadence every 9-12 months for sustainable growth.

• Metrics beyond start forms, such as active patients, discontinuation rates, coverage, and net revenue, are used to assess performance.

• Over 500 prescribers in the first six months, with more than half of top 300 accounts having written and most having rewritten prescriptions.

• Virtual sales team targets physicians with few patients, while in-person reps focus on high-volume accounts.

• Refill rates are considered strong, with net revenue reflecting ongoing patient engagement.

Market access and reimbursement

• Over 130 million lives covered, with payments from Medicaid, Medicare, and commercial channels; more than 40 states reimbursing via Medicaid.

• Three largest PBMs have favorable policies, and market access is described as strong and growing.

• Free drug provided in three categories: quick start, bridge (e.g., clinical trial patients), and PAP, with total free drug at steady state expected to be about 20%, currently lower.

• Ongoing payer and state-level challenges are expected but are being managed.

Physician and patient engagement

• Education efforts include disease state materials, webinars, peer-to-peer events, and expert-on-demand support.

• KOLs influence about 40% of TAM; peer-to-peer and direct outreach help expand prescriber base.

• Many KOLs have not yet offered the drug to all eligible patients; ongoing uptake expected as patients return for regular visits.

• PACE team of nurse educators supports families with drug expectations, titration, and side effect management, with near real-time response.

• Positive patient stories are being collected and shared, highlighting improved quality of life.